Advanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront.

The authors report the case of a 21-year-old woman that presented a Pseudo Meigs' syndrome, secondary to a pure endodermal sinus tumour (yolk sac tumour). Fine needle aspiration biopsy was compatible with high-grade carcinoma and the alpha fetoprotein (αFP) was at 13,185 U/ml. Cytoreductive surgery was performed, followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy.

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

INTRODUCTION: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer. METHODS: Her-2-negative breast cancer patients with tumours larger than 2 cm were eligible for dose-escalation trial (classic 3+3 method). RESULTS: The recommended phase II dose (RP2D) was 150 mg BID of nintedanib combined with standard dose of weekly paclitaxel followed by adriamycin plus cyclophosphamide. The dose-limiting toxicity was transaminase elevation. At the RP2D, the dose intensity was ∼100%. The pathologic complete response was 50%. CONCLUSIONS: The combination allows the delivery of full-dose intensity, while efficacy seems promising.

Utilidad de la PET/TC en el manejo del cáncer de vulva / Utility of the PET/CT in vulvar cancer management

Objetivo: Describir el impacto clínico de la PET/TC en el manejo delas pacientes con cáncer de vulva. Material y métodos: Análisis retrospectivo de 13 estudios de PET/TC con 18F-FDG (6 de estadificación y 7 por sospecha de recurrencia), correspondientes a 10 pacientes diagnosticadas de cáncer de vulva mediante biopsia, con una edad media de 64,5 años. Se analizó cualitativamente el estudio PET/TC preoperatorio, según la región de la lesión. Se realizó exéresis quirúrgica, abordando todas las zonas sospechosas según el estudio de PET/TC. Se comparó con el análisis histopatológico. Resultados: Se encontró captación patológica vulvar en 9 de los 13 estudios, e invasión de estructuras adyacentes (uretra, ano o vagina) en 5 de ellos. En 3 estudios se consideró afectados los ganglios inguinofemorales, y en uno de ellos apareció también afectación ganglionar pélvica. Cuatro de los estudios presentaron diseminación extralinfática: 3 en el pulmón y uno en la fosa isquiorrectal. La PET/TC mostró una sensibilidad para la detección de la lesión vulvar del 100% en carcinoma epidermoide y del 60% en el no epidermoide. Se encontró un falso positivo en cuanto a invasión local debido a contaminación urinaria. Uno de los estudios con metástasis pulmonares procedía de un tumor de mama sincrónico. Todos los niveles ganglionares patológicos detectados en la PET/TC fueron confirmados en el estudio histopatológico. No se identificaron nuevas lesiones en la cirugía. La PET/TC cambió el manejo terapéutico en 8 de los 13 estudios (61,5%). Conclusiones: La PET/TC se postula como una prueba de imagen útil en el manejo del cáncer de vulva, particularmente en la identificación de la afectación ganglionar, pudiendo influir tanto en la planificación quirúrgica como en el manejo clínico. Se necesitan series más extensas que confirmen nuestros hallazgos (AU)

Objective: To describe the clinical impact of PET/CT in the management of patients with vulvar cancer. Material and methods: Retrospective analysis of 13 PET/CT studies with 18F-FDG (6 staging and 7 suspected recurrence) corresponding to 10 patients diagnosed with vulvar cancer by biopsy, with a mean age of 64.5 years. The preoperative PET/CT study was analyzed qualitatively according to the lesion region. Surgical excision was carried out, covering all the suspected areas according to the PET/CT study. This was compared with the histopathologic analysis. Results: Abnormal vulvar PET/CT uptake was found in 9 out of the 13 studies and invasion of adjacent structures in 5 of them (urethra, perineal, vagina). The inguinal-femoral lymph nodes were considered as affected in 3 studies and one pelvic lymph node was also affected. Four of the studies had extralymphatic involvement: 3 in lung and 1 in ischiorectal fossa. The PET/CT showed a 100% sensitivity for the detection of the vulvar lesion in squamous cell carcinomas and 60% in non-squamous cell ones. There was a false positive result for local invasion due to urine contamination. One of the studies with lung metastases was related to a synchronous breast tumor. All the pathological lymph node levels detected in the PET/CT study were confirmed in the histopathology study. No new lesions were identified by surgery. PET/CT changed the therapeutic management in 8/13 studies (61.5%). Conclusions: PET/CT is postulated as a useful imaging test for the management of vulvar cancer, mainly in the identification of nodal metastases. It may affect both surgical planning and clinical management. Larger series are needed to confirm our findings (AU)

[Utility of the PET/CT in vulvar cancer management]. / Utilidad de la PET/TC en el manejo del cáncer de vulva.

OBJECTIVE: To describe the clinical impact of PET/CT in the management of patients with vulvar cancer. MATERIAL AND METHODS: Retrospective analysis of 13 PET/CT studies with (18)F-FDG (6 staging and 7 suspected recurrence) corresponding to 10 patients diagnosed with vulvar cancer by biopsy, with a mean age of 64.5 years. The preoperative PET/CT study was analyzed qualitatively according to the lesion region. Surgical excision was carried out, covering all the suspected areas according to the PET/CT study. This was compared with the histopathologic analysis. RESULTS: Abnormal vulvar PET/CT uptake was found in 9 out of the 13 studies and invasion of adjacent structures in 5 of them (urethra, perineal, vagina). The inguinal-femoral lymph nodes were considered as affected in 3 studies and one pelvic lymph node was also affected. Four of the studies had extralymphatic involvement: 3 in lung and 1 in ischiorectal fossa. The PET/CT showed a 100% sensitivity for the detection of the vulvar lesion in squamous cell carcinomas and 60% in non-squamous cell ones. There was a false positive result for local invasion due to urine contamination. One of the studies with lung metastases was related to a synchronous breast tumor. All the pathological lymph node levels detected in the PET/CT study were confirmed in the histopathology study. No new lesions were identified by surgery. PET/CT changed the therapeutic management in 8/13 studies (61.5%). CONCLUSIONS: PET/CT is postulated as a useful imaging test for the management of vulvar cancer, mainly in the identification of nodal metastases. It may affect both surgical planning and clinical management. Larger series are needed to confirm our findings.